The strong revenue growth and profitability inflection, combined with the clean balance sheet post-convertible note conversion, support a bullish thesis. Watch for continued YORVIPATH uptake and the upcoming EMA decision on YUVIWEL in Q4 2026, which could drive further upside. The stock's addition to Russell indexes may also attract passive inflows.
Price Chart
Executive Summary
Ascendis Pharma reported Q2 2026 product revenue of €315M (+105% YoY), driven by YORVIPATH (€252M) and SKYTROFA (€55M), and achieved its first-ever operating profit of €220M (65% margin). The company also settled all $575M in convertible notes, converting them to equity, and reported non-IFRS diluted EPS of €0.90, which is in line with the Street consensus of $0.77 (€0.71) — a modest beat. The strong top-line growth and profitability inflection are the key drivers, but the GAAP EPS of €2.83 includes a one-time €158M PRV sale and a €704M deferred tax asset recognition, masking underlying operating leverage.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue €339M vs €158M YoY (+115%)
- Product revenue €315M, +105% YoY, driven by YORVIPATH €252M (+145% YoY)
- First-ever operating profit of €220M (65% margin) vs operating loss of €53M YoY
- Non-IFRS operating profit €92M (27% margin) vs non-IFRS operating loss of €23M YoY
- Non-IFRS diluted EPS €0.90 vs consensus $0.77 (~€0.71), a ~27% beat
- Converted all $575M of 2.25% Convertible Senior Notes due 2028 to equity, eliminating €719M in liabilities
- Cash and equivalents €812M as of June 30, 2026, up from €616M at Dec 31, 2025
- YUVIWEL revenue €8M with >220 unique patient enrollments in the U.S.
- Added to Russell 3000, 1000, 2500, and Midcap Indexes in June 2026
Financial Impact
Product revenue growth of 105% YoY to €315M; operating profit swing of +€273M YoY; non-IFRS EPS beat of ~27% vs consensus
Risk Factors
- Revenue growth is heavily dependent on YORVIPATH (80% of product revenue); any competitive or reimbursement headwind could slow momentum
- SG&A expenses rose 61% YoY to €173M, reflecting commercial expansion costs that may pressure margins if revenue growth decelerates
- Non-IFRS adjustments are significant — GAAP net profit includes €158M one-time PRV sale and €704M deferred tax asset recognition, which are non-recurring
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344408 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access